Indole Compound Therapy for Multiple Sclerosis Recurrence Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic drugs for multiple sclerosis (MS) are insufficient in treating or preventing the recurrence and progression of the disease, particularly in relapsing-remitting, primary progressive, and secondary progressive MS, and do not effectively manage symptoms such as weakness, ataxia, sensory neuropathy, dysuria, dyschezia, mental disorders, and memory disorders.
Innovation Solution
Compound A, N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-indol-6-yl]-N-methyl-(2S)-2-(morpholin-4-yl)propanamide, and its pharmaceutically acceptable salts, particularly the monohydrochloride, are used to treat or prevent MS, including its recurrence and progression, by reducing disease severity and managing symptoms through oral or parenteral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutic drugs for multiple sclerosis are used, then treatment of MS is provided, but treatment effect is insufficient for preventing recurrence and progression
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of indole compounds to create Compound A with optimized ITK inhibitory activity. This structural modification results in enhanced therapeutic efficacy for preventing MS recurrence and progression while maintaining acceptable side effect profiles, directly addressing the insufficiency of existing treatments
2Reliability
If FTY-720 is used for treating multiple sclerosis, then some treatment effect is achieved, but it is insufficient for certain cases
Solution Approach 1:
The patent employs parameter changes by developing Compound A with modified chemical parameters compared to FTY-720. This creates a new therapeutic agent with enhanced ITK inhibitory activity and improved adaptability to different MS cases including relapsing-remitting, primary progressive, and secondary progressive MS, overcoming the limitations of FTY-720
3Quantity of substance
If low molecular ITK inhibitors are used, then ITK inhibition is achieved, but treatment of MS is not effectively described
Solution Approach 1:
The patent applies parameter changes by optimizing the molecular structure of indole compounds to achieve Compound A, which maintains low molecular weight for ITK inhibition while significantly improving MS treatment efficacy. The specific chemical modifications enhance both the quantity of ITK inhibition and the reliability of MS treatment outcomes
Solution Approach 2:
The patent employs composite materials by creating Compound A as a sophisticated indole compound structure that combines multiple functional groups (indole, indazole, morpholine) to achieve both ITK inhibition and enhanced MS treatment efficacy, surpassing simple low molecular ITK inhibitors
Data Source
AI summary
The present invention provides a therapeutic agent or prophylactic agent for multiple sclerosis, containing N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-indol-6-yl]-N-methyl-(2S)-2-(morpholin-4-yl)propanamide or a pharmaceutically acceptable salt thereof.